Laurus Labs Q2 FY24 consolidated PAT up QOQ at Rs. 36.95 Cr

Laurus Labs has reported total income of Rs. 1226.23 crores during the period ended September 30, 2023

Need to include ASMD as a notified condition in the National Policy for rare diseases

ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another

Daiichi Sankyo, Merck collaborate to develop and commercialize three Daiichi Sankyo DXd ADCs

Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months

USFDA approves Pfizer’s Velsipity for adults with Ulcerative Colitis

Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials

Syngene Q2 FY23-24 revenue from operations up 18.5% to Rs 910 Cr

Profit after tax (before exceptional items) up 23% to Rs 215 crores

Zydus appoints Punit Patel as President and CEO, Americas

Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace

AstraZeneca’s Tagrisso to lead lung cancer small molecule market with over $7 billion sales by 2029, says GlobalData

Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio

Moberg Pharma has completed enrollment to the Phase 3 study for MOB-015 in North America

Menarini strengthens its presence in aesthetic dermatology in India

The introduction of 'Definisse Core Filler' is a testament to the company's premium scientific-based innovation

Merck and Eisai update on Two Phase 3 Trials Evaluating Keytruda plus Lenima for cell lung cancer

The companies will work with investigators to share the results with the scientific community